Additionally, treatment with sEH inhibitors have been shown to improve heart function, reducing cardiac hypertrophy and fibrosis in heart failure models (Qiu et al., 2011; Merabet et al., 2012; Stevenson et al., 2019). Here, EPHX2 is linked to heart failure.